CLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Clorox Co (CLX) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is currently in a downtrend, with weak financial performance and no significant positive catalysts. While the RSI indicates oversold conditions, suggesting a potential rebound, the lack of strong trading signals and mixed analyst sentiment make it prudent to hold off on buying for now.
The stock is in a clear downtrend with a regular market change of -3.18%. The MACD is negatively expanding, RSI is at 15.918 (oversold), and moving averages are converging. Key support is at 112.505, close to the current price, indicating limited downside potential in the short term. However, no clear reversal signals are present.
The company's acquisition of GOJO Industries (maker of Purell) is seen as a strategic move to improve its portfolio and distribution capabilities, which could provide long-term benefits.
Weak Q2 financial performance with revenue down -0.77% YoY, net income down -18.65% YoY, and EPS down -16.77% YoY. Gross margin also declined to 42.86%. Analysts maintain neutral ratings with no strong upward momentum in price targets. Additionally, there is no recent news or significant insider/hedge fund trading activity to suggest immediate upside potential.
In Q2 2026, Clorox reported declining financial metrics across the board. Revenue dropped by -0.77% YoY to $1.67 billion, net income fell by -18.65% YoY to $157 million, and EPS declined by -16.77% YoY to $1.29. Gross margin also decreased by -1.81% YoY to 42.86%. This indicates ongoing challenges in managing costs and maintaining profitability.
Analysts have raised price targets slightly, but most maintain neutral ratings. The highest price target is $132, and the lowest is $112, with the current price at $113.71. Analysts cite mixed organic sales trends and margin pressures as key concerns, despite some optimism around the GOJO acquisition.
